Sami-Sabinsa Group to Set Up New Manufacturing Facility in Hassan, Karnataka at an Investment of Rs. 200 Crore

Sami-Sabinsa Group

"The vision of a research scientist and a passionate entrepreneur takes on social and commercial expressions." This, in short, explains the genesis and growth of Sami-Sabinsa Group.

Sami-Sabinsa Group is a research-focused multinational health science company that was founded in 1991 by the late Dr. Muhammed Majeed, an internationally renowned scientist and entrepreneur in the field of evidence-based medicine. The company is a leading manufacturer of nutraceuticals and cosmeceutical ingredients, standardized herbal extracts, enzymes, probiotics, nutricosmetics, nutritional fine chemicals, and specialty chemicals.
Read More...

Photo caption: Dr. Muhammed Majeed, Founder & Chairman, Sami-Sabinsa Group, Dr. Anju Majeed, Director & Sr. Scientist, Mr V.G Nair, Director & CEO and Mr. Madhu Subramanian, Director, unveiled the artist’s impression of the upcoming new facility to the media at the press meet.

First phase of plant will be functional in 2021 and is part of Sami-Sabinsa Group’s strategy to expand existing ingredient growth and focus on new innovative products

Bengaluru, January 29, 2020: A pioneer and global leader in health science and nutraceuticals, Sami-Sabinsa Group today announced the launch of its new manufacturing facility at Pharma SEZ Industrial Area, Hassan, Karnataka. The first phase of the plant will house a 40,000 square metres world-class Active Nutraceutical Ingredients (ANI) manufacturing unit, with an annual capacity of 300 tons and will be functional by 2021. The new facility with a planned investment of Rs. 200 crore is part of the Sami-Sabinsa Group’s growth strategy.

Speaking at a press conference held in the city today, Dr. Muhammed Majeed, Founder & Chairman, Sami-Sabinsa Group said, “World over, consumers are seeking alternatives to better health and looking for food and beverages that supply all their nutritional needs. As the pioneer and among the few Indian companies to have created a global market for patented formulations in the health space, we are committed to a research-oriented, science-based approach towards developing products that make lives healthier and better. The upcoming facility at Hassan, is a reinforcement of this commitment. The new unit when operational will play a pivotal role in boosting our exports further and help us to double our revenues. The first phase, once functional in 2021, will provide employment to around 400 qualified workforce in the fast-growing industrial region of Hassan”.

Mr. V.G Nair, Director and CEO, Sami-Sabinsa Group added, “Sami-Sabinsa’s new plant is designed to be world-class, meeting international standards & requirements and will house a high quality, environment-friendly Zero Liquid Discharge (ZLD) facility ensuring energy efficiency, responsible water management and biodiversity development. The ANI facility is 100% cGMP and regulatory compliant”.

Photo caption: Sami-Sabinsa team at the press meet in Bengaluru

The Hassan plant is Sami-Sabinsa Group’s 8^th global manufacturing facility, in addition to its current units located in Peenya, Dobaspet, Kunigal, Hyderabad, Nelamangala and USA.

When fully functional, the new plant will not only expand the Group’s overall manufacturing capacity but also strengthen Sami-Sabinsa Group’s ranking as among India’s foremost and largest global nutraceuticals major.

According to latest industry reports, the global market for nutraceuticals is set for robust growth. It is expected to reach $373 billion by 2025, growing at a CAGR of 7.5%, as per PMMI Business Intelligence report. The Indian nutraceuticals market has flourished to a $3 billion industry and is forecast to touch $8.1 billion by 2022.

What We Do

Sami-Sabinsa Group Limited (formerly Sami Labs Limited), a pioneer and global leader in health science, is a leading producer of nutraceuticals, cosmeceuticals, standardized herbal extracts, fine chemicals, specialty chemicals, probiotics, and enzymes.

The company’s corporate R&D encompasses independent research divisions, including Natural Drugs, Phytochemistry, Synthetic Chemistry, Tissue Culture, Biotechnology, Analytical R&D, Biological Research, Microbiology, and Formulation R&D. These divisions collaborate in a synergistic work model to produce products that adhere to international standards.

With the collective wisdom of over 120 research scientists, Sami-Sabinsa Group has developed standardized natural extracts that render alternative therapy to emerging nutritional and health requirements across the globe.